MIR5195: A Potential Drug Target and Biomarker (G100847062)

Target Name: MIR5195

NCBI ID: G100847062

MIR5195

Other Name(s): MicroRNA 5195 | microRNA 5195 | hsa-miR-5195-3p | hsa-mir-5195 | hsa-miR-5195-5p

MIR5195: A Potential Drug Target and Biomarker

MIR5195 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the superfamily of immediate-early gene (SEG) proteins, which are characterized by the presence of a short interregeneration number (IRN) gene. MIR5195 is expressed in most tissues of the body and has been shown to play a role in various physiological processes, including cell signaling, inflammation, and stress resistance.

One of the most promising aspects of MIR5195 is its potential as a drug target. The SEG proteins have been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MIR5195 has been shown to be involved in several signaling pathways that are involved in these diseases, including the TGF-β pathway, the NF-kappa-B pathway, and the PI3K/AKT pathway.

In addition to its potential as a drug target, MIR5195 has also been shown to be a potential biomarker for several diseases. The SEG proteins have been shown to be involved in various cellular processes that are involved in disease development, including inflammation, cell proliferation, and survival. MIR5195 has been shown to be involved in these processes and has been used as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of MIR5195 as a drug target is its potential to target a specific protein with high affinity. The TGF-β pathway is a well-established pathway that is involved in the development and maintenance of tissues, including muscles, bones, and organs. MIR5195 has been shown to be involved in this pathway and has been shown to play a role in the regulation of TGF-β signaling.

In addition to its involvement in the TGF-β pathway, MIR5195 has also been shown to be involved in several other signaling pathways that are involved in disease development. The NF-kappa-B pathway is a signaling pathway that is involved in inflammation and stress resistance, and MIR5195 has been shown to be involved in this pathway.

MIR5195 has also been shown to be involved in the PI3K/AKT pathway, which is a signaling pathway that is involved in cell survival and angiogenesis. This pathway is important for the development and maintenance of tissues and is involved in the regulation of various cellular processes, including cell growth, angiogenesis, and inflammation.

In conclusion, MIR5195 is a protein that has been shown to play a role in various physiological processes and has been shown to be involved in several signaling pathways that are involved in disease development. As a potential drug target, MIR5195 is a promising target for the development of new therapies for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, MIR5195 may also be a potential biomarker for these diseases. Further research is needed to fully understand the role of MIR5195 in disease development and to develop new treatments based on this protein.

Protein Name: MicroRNA 5195

The "MIR5195 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5195 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets